Bone and soft tissue sarcomas, tumors of the skinBone and soft tissue sarcomas, tumors of the skinСаркомы костей, мягких тканей и опухоли кожи2219-46142782-3687Publishing House ABV Press12110.17650/2782-3687-2021-13-3-16-27SOFT TISSUE SARCOMASСАРКОМЫ МЯГКИХ ТКАНЕЙTrabectedin in the treatment of soft tissue sarcomas: up to date dataРоль трабектедина в лечении сарком мягких тканей: обзор современных данныхhttps://orcid.org/0000-0003-4927-5585FedenkoA. A.ФеденкоА. А.
Russian Federation

3 2nd Botkinskiy Proezd, Moscow 125284, Russia

Россия, 125284 Москва, 2-й Боткинский проезд, 3

https://orcid.org/0000-0002-5548-3295TararykovaA. A.ТарарыковаА. А.
Russian Federation

Anastasia Alekseevna Tararykova

24 Kashirskoe Shosse, Moscow 115478, Russia

Анастасия Алексеевна Тарарыкова

Россия, 115478 Москва, Каширское шоссе, 24

anastasiatararykova@gmail.comNational Medical Research Radiological Center, Ministry of Health of RussiaФГБУ «Национальный медицинский исследовательский центр радиологии» Минздрава РоссииN.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaФГБУ «Национальный медицинский исследовательский центр онкологии им. Н. Н. Блохина» Минздрава России1811202113316261711202117112021Copyright ©; 2021, Fedenko A.A., Tararykova A.A.Copyright ©; 2021, Феденко А.А., Тарарыкова А.А.2021Fedenko A.A., Tararykova A.A.Феденко А.А., Тарарыкова А.А.https://creativecommons.org/licenses/by/4.0https://sarbon.abvpress.ru/jour/article/view/121

Soft tissue sarcomas are a rare heterogeneous group of malignant tumors with mesenchymal nature. Soft tissue sarcomas accounts for less than 1 % of all cancers. Low efficiency of chemotherapy for soft tissue sarcomas, especially in advanced disease, is a burning issue. Trabectedin is one of the active agents approved for the treatment of advanced soft tissue sarcomas after the failure of standard chemotherapy. The article provides a literature review of the latest world-wide data of the effectiveness and role of trabectedin in the modern approach of soft tissue sarcomas treatment.

Саркомы мягких тканей – редкая гетерогенная группа злокачественных опухолей мезенхимального происхождения, которые составляют менее 1 % всех онкологических заболеваний. Актуальная проблема лекарственной терапии данной патологии, особенно при распространенном процессе, – низкая эффективность применяемых схем лечения. Трабектедин является одним из активных противоопухолевых агентов, одобренных для лечения сарком мягких тканей в случае неэффективности стандартной химиотерапии.

В данной статье представлен обзор публикаций по теме эффективности трабектедина и его роли в лечении пациентов с саркомами мягких тканей.

soft tissue sarcomatrabectedinliposarcomaleiomyсаркома мягких тканейтрабектединлипосаркомалейомиосаркомаMalignant neoplasms in Russia in 2019 (morbidity and mortality). Ed. by A.D. Kaprin, V.V. Starinsky, A.O. Shakhzadov. Moscow: P.A. Herzen Moscow State Medical Research Institute – branch of the Federal State Budgetary Institution "NMIC of Radiology" of Ministry of Health of Russia, 2020. 252 p..Злокачественные новообразования в России в 2019 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадова. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2020. 252 с.Amercan Cancer Society. Cancer Facts & Figures 2017. Atlanta Am Cancer Soc 2017. Avaliable at: https://www.cancer.org/research/cancer-facts-statistics/all-cancerfacts-figures/cancer-facts-figures-2017.html.Le Cesne A., Blay J.-Y., Cupissol D. et al. A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trial. Ann Oncol 2021;32(8):1034–44. DOI: 10.1016/j.annonc.2021.04.014.Delaloge S., Yovine A., Taamma A. et al. Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients – preliminary evidence of activity. J Clin Oncol 2001;19(5):1248–55. DOI: 10.1200/JCO.2001.19.5.1248.Yovine A., Riofrio M., Blay J.Y. et al. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol 2004;22(5):890–9. DOI: 10.1200/JCO.2004.05.210.Garcia-Carbonero R., Supko J.G., Manola J. et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol 2004;22(8):1480–90. DOI: 10.1200/JCO.2004.02.098.Blay J.Y., Italiano A., Ray-Coquard I. et al. Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program. BMC Cancer 2013;13:1–8. DOI: 10.1186/1471-2407-13-64.Herrero A.B., Martín-Castellanos C., Marco E. et al. Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin. Cancer Res 2006;66(16):8155–62. DOI: 10.1158/0008-5472.CAN-06-0179.Grosso F., Jones R.L., Demetri G.D. et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol 2007;8(7):595–602. DOI: 10.1016/S1470-2045(07)70175-4.Demetri G.D., Chawla S.P., Mehren M. von et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol 2009;27(25):4188–96. DOI: 10.1200/JCO.2008.21.0088.Demetri G.D., Chawla S.P., Mehren M. von et al. Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial. J Clin Oncol 2015;34(8):786–93. DOI: 10.1200/JCO.2015.62.4734.Patel S., Mehren M., Reedet D.R. at al. Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma. Cancer 2019;125(15):2610–20. DOI: 10.1002/cncr.32117.De Sande González L.M., Martin-Broto J., Kasper B. et al. Real-world evidence of the efficacy and tolerability of trabectedin in patients with advanced soft-tissue sarcoma. Expert Rev Anticancer Ther 2020;20(11):957–63. DOI: 10.1080/14737140.2020.1822744.Samuels B.L., Chawla S., Patel S. et al. Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study. Ann Oncol 2013;24(6):1703–9. DOI: 10.1093/annonc/mds659.Ploner F., Lamm W., Schur S. et al. The Austrian experience with trabectedin in non-selected patients with metastatic soft tissue sarcoma (STS). J Cancer Res Clin Oncol 2013;139(8):1337–42. DOI: 10.1007/s00432-013-1447-8.Gounaris I., Hatcher H.M., Davidson D. et al.Trabectedin for advanced soft tissue sarcomas: A single institution experience. Futur Oncol 2014;10(11):1843–51. DOI: 10.2217/FON.14.10.Le Cesne A., Ray-Coquard I., Duffaud F. et al. Trabectedin in patients with advanced soft tissue sarcoma: a retrospective national analysis of the French Sarcoma Group. Eur J Cancer 2015;51(6):742–50. DOI: 10.1016/j.ejca.2015.01.006.De Sanctis R., Marrari A., Marchetti S. et al. Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipoand leiomyosarcoma. Drug Des Devel Ther 2015;9:5785–91. DOI: 10.2147/DDDT.S92395.Buonadonna A., Benson C., Casanova J. et al. A noninterventional, multicenter, prospective phase IV study of trabectedin in patients with advanced soft tissue sarcoma. Anticancer Drugs 2017;28(10):1157–65. DOI: 10.1097/CAD.0000000000000560.Shamai S., Merimsky O. Trabectedin for advanced soft tissue sarcoma: ten year real-life perspective. Isr Med Assoc J 2018;20(10):599–603. DOI: 10.1200/JCO.2017.35.15_suppl.11060.Kotecki N., Cesne A.L., Tresch-Bruneel E. et al. Update of the T-DIS randomized phase II trial: trabectedin rechallenge versus continuation in patients (pts) with advanced soft tissue sarcoma (ASTS). Ann Oncol 2016;27(Suppl 6):vi486. DOI: 10.1093/annonc/mdw388.12.Paz-Ares L., López-Pousa A., Poveda A. et al. Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating cotreatment with dexamethasone. Invest New Drugs 2012;30(2)729–40. DOI: 10.1007/s10637-010-9561-9.Jordan K., Jahn F., Jordan B. et al. Trabectedin: Supportive care strategies and safety profile. Crit Rev Oncol Hematol 2015;94(3):279–90. DOI: 10.1016/j.critrevonc.2015.02.012.Shewach D.S., Lawrence T.S. Recognition of a new chemotherapeutic vesicant: trabectedin (ecteinascidin-743) extravasation with skin and soft tissue damage. J Clin Oncol 2008;27(33):198–200. DOI: 10.1200/JCO.2008.21.6473.Reuben D.Y. A prolonged response and characteristics of trabectedin treatment of metastatic soft tissue sarcoma. J Med Cases 2021;12(4):160–3. DOI: 10.14740/jmc3655.Cordeiro M., Casan J.M., Rodrigues J. et al. Long-term response after 94 cycles of trabectedin in a patient with metastatic leiomyosarcoma of the lower extremity. Case Rep Oncol 2020;13(1):113–9. DOI: 10.1159/000505393.Cesne A.L., Judson I., Maki R. et al. Trabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: a retrospective pooled analysis of five phase II trials. Br J Cancer 2013;109(7):1717–24. DOI: 10.1038/bjc.2013.524.Blay J.Y., Blay J.Y., Judson I. et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group trial. J Clin Oncol 2005;23(3):576–84. DOI: 10.1200/JCO.2005.01.180.Garcia-Carbonero R., Supko J.G., Maki R.G. et al. Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study. J Clin Oncol 2005;23(24):5484–92. DOI: 10.1200/JCO.2005.05.028.Kawai A., Hartzell T.L., Sinha I. el al. Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocationrelated sarcoma: a randomised, open-label, phase 2 study. Lancet Oncol 2015;16(4):406–16. DOI: 10.1016/S1470-2045(15)70098-7.Grosso F., D’Ambrosio L., Zucchetti M. et al. Pharmacokinetics, safety, and activity of trabectedin as first-line treatment in elderly patients who are affected by advanced sarcoma and are unfit to receive standard chemotherapy: a phase 2 study (TR1US study) from the Italian Sarcoma Group. Cancer 2020;126(21):4726–34. DOI: 10.1002/cncr.33120.Pautier P., Floquet A., Chevreau C. et al. Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial. Lancet Oncol 2015;16(4):457–64. DOI: 10.1016/S1470-2045(15)70070-7.Martin-Broto J., Pousa A.L., Peñas Las de R. et al. Randomized phase II study of trabectedin and doxorubicin compared with doxorubicin alone as first-line treatment in patients with advanced soft tissue sarcomas: a Spanish group for research on sarcoma study. J Clin Oncol 2016;34(19):2294–302. DOI: 10.1200/JCO.2015.65.3329.Pautier P., Floquet A., Chevreau C. et al. A single-arm multicentre phase II trial of doxorubicin in combination with trabectedin in the first-line treatment for leiomyosarcoma with long-term follow-up and impact of cytoreductive surgery. ESMO Open;2021;6(4):100209. DOI: 10.1016/j.esmoop.2021.100209.Pautier P., Italiano A., Piperno-Neumann S. et al. LMS-04 study: a randomised, multicenter, phase III study comparing doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin in non-progressive patients as first-line therapy, in patients with metastatic or unresectable leiomyosarc. Ann Oncol 2021;32(5):S1283–346. DOI: 10.1016/annonc/annonc741.Grosso F., Sanfilippo R., Virdis E. et al. Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series. Ann Oncol 2009;20(8):1439–44. DOI: 10.1093/annonc/mdp004.Takahashi M., Takahashi S., Araki N. et al. Efficacy of trabectedin in patients with advanced translocation related sarcomas: pooled analysis of two phase II studies. Oncologist 2017;22(8):979–88. DOI: 10.1634/theoncologist.2016-0064.Martínez-Trufero J., Sande-González de L.M., Luna P. et al. A growth modulation indexbased GEISTRA SCORE as a new prognostic tool for trabectedin efficacy in patients with advanced soft tissue sarcomas: a Spanish group for sarcoma research (GEIS) retrospective study. Cancers (Basel) 2021;13(4):1–15. DOI: 10.3390/cancers13040792.Von Hoff D.D. There are no bad anticancer agents, only bad clinical trial designs-twentyfirst Richard and Hinda Rosenthal Foundation Award Lecture. Clin Cancer Res 1998; 4(5):1079–86.Gronchi A., Hindi N., Cruz J. et al. Trabec-tedin and radiotherapy in soft tissue sarcoma (trasts): results of a phase i study in myxoid liposarcoma from Spanish (GEIS), Italian (ISG), French (FSG) Sarcoma Groups. Clinical Medicine 2019;9:35–43. DOI: 10.1016/j.eclinm.2019.03.007.Hindi N., García I.C., Sánchez-Camacho A. et al. Trabectedin plus radiotherapy for advanced soft-tissue sarcoma: experience in forty patients treated at a sarcoma reference center. Cancers (Basel) 2020;12(12):3740. DOI: 10.3390/cancers12123740.